Ionis Q2 revenue $225M (+20% YoY); operating loss narrows to $66M; key pipeline milestones

IONIS PHARMACEUTICALS INC

2024-Q2 EPS reported -$1.43 revenue$344,748,000

Total revenue $225M (up 20% YoY); loss from operations $66M vs $91M loss in Q2 2023; non-GAAP loss from ops $35M.
WAINUA Q2 royalty revenue $4M; approved in Canada; U.S. launch progressing with AstraZeneca.
Olezarsen NDA for FCS accepted for Priority Review, PDUFA Dec 19, 2024; Phase 3 sHTG studies fully enrolled, data H2:2025.
Donidalorsen Phase 3 OASIS data published in NEJM; preparing U.S. NDA and EU MAA for HAE.
Cash and short-term investments $2.1B; reaffirmed 2024 guidance; projects year-end cash $1.7B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.